The Neuroscience and Animal Models Core (NAM) Core serves both as a resource for TMARC and as a scientific platform for translating clinical observations into appropriate in vitro and in vivo experimental models to study mechanisms of disease associated with methamphetamine (METH)/HIV-induced brain injury. The Core Resource Objectives include: 1) Provide transgenic (gp120 and ITat) animals that exhibit central nervous system (CNS) pathology associated with HIV;2) Provide the infrastructure for molecular analysis of the pathologic substrates in METH/HIV associated brain injury in HIV transgenic animals exposed to METH; furthermore, through linkage to the California NeuroAIDS Tissue Network (CNTN), the NAM Core will also access banked brain tissues that will support the translational aim of cross validating animal and human neuropathology, and finally, for in vitro studies we will provide experimental systems based on primary human neuroglial cultures, neuronal cell lines, and brain vascular smooth muscle cells;3) Foster translational research ideas by supporting Pilot studies and training in the field of experimental neuropathology for young investigators. The Core Scientific Objectives include: 1) Analyze the neuropathology induced by METH exposure in HIV transgenic animals, young and aged;2) Design neuropathologic analyses of HIV brains banked through the CNTN focused on aging, vascular and immune-mediated pathology associated with METH;3) Through support of Pilot studies, the NAM Core will generate preliminary data for future developmental projects within TMARC focused on issues such as chronic brain inflammation, metabolic and oxidative stress, aging and brain vascular pathology, METH effects on social cognition in HIV transgenic animals, and neuroprotective interventions.
Studies within the NAM Core will generate experimental neuropathology findings to be validated in the clinical setting. The long-term goals include validation of the neuropathologic correlates vis-a-vis clinical evaluations, development of projects targeting new mechanisms of disease and pioneering therapeutic interventions in the METH/HIV brain injury.
|Oppenheim, Hannah; Paolillo, Emily W; Moore, Raeanne C et al. (2018) Neurocognitive functioning predicts frailty index in HIV. Neurology 91:e162-e170|
|Walker, Keenan A; Brown, Gregory G (2018) HIV-associated executive dysfunction in the era of modern antiretroviral therapy: A systematic review and meta-analysis. J Clin Exp Neuropsychol 40:357-376|
|Stecher, Melanie; Hoenigl, Martin; Eis-Hübinger, Anna Maria et al. (2018) Hotspots of Transmission Driving the Local Hiv Epidemic in the Cologne-Bonn Region, Germany. Clin Infect Dis :|
|Paolillo, Emily W; Obermeit, Lisa C; Tang, Bin et al. (2018) Smartphone-based ecological momentary assessment (EMA) of alcohol and cannabis use in older adults with and without HIV infection. Addict Behav 83:102-108|
|Thaney, Victoria E; Kaul, Marcus (2018) Type I Interferons in NeuroHIV. Viral Immunol :|
|Soontornniyomkij, Virawudh; Umlauf, Anya; Soontornniyomkij, Benchawanna et al. (2018) Association of antiretroviral therapy with brain aging changes among HIV-infected adults. AIDS 32:2005-2015|
|Thaney, Victoria E; Sanchez, Ana B; Fields, Jerel A et al. (2018) Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research. J Neurovirol 24:156-167|
|Kesby, James P; Chang, Ariel; Markou, Athina et al. (2018) Modeling human methamphetamine use patterns in mice: chronic and binge methamphetamine exposure, reward function and neurochemistry. Addict Biol 23:206-218|
|Hoenigl, Martin; Jain, Sonia; Moore, David et al. (2018) Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. Emerg Infect Dis 24:|
|Moore, David J; Pasipanodya, Elizabeth C; Umlauf, Anya et al. (2018) Individualized texting for adherence building (iTAB) for methamphetamine users living with HIV: A pilot randomized clinical trial. Drug Alcohol Depend 189:154-160|
Showing the most recent 10 out of 148 publications